EJPMR, 2026, 13(11), 469-475 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

REGULATORY REQUIREMENTS FOR APPROVAL OF VACCINES IN INDIA IN COMPARISON WITH THE PHILIPPINES

Dr. P. Ashok Kumar*, Lavakumar J. N., Rochana B. V., Chinmayi N., Ananya G. A., Karthik P.

Department of Regulatory Affairs, Sree Siddaganga College of Pharmacy, 1st Left Cross, 3rd Block, Mahalakshmi Nagar, Near Railway Gate, 80 Feet Road, Batawadi, Tumkur – 572103, Karnataka, India.

***Corresponding Author: Dr. P. Ashok Kumar**

Department of Regulatory Affairs, Sree Siddaganga College of Pharmacy, 1st Left Cross, 3rd Block, Mahalakshmi Nagar, Near Railway Gate, 80 Feet Road, Batawadi, Tumkur – 572103, Karnataka, India.

DOI: https://doi.org/10.5281/zenodo.23914007

How to cite this Article: Dr. P. Ashok Kumar*, Lavakumar J. N., Rochana B. V., Chinmayi N., Ananya G. A., Karthik P. (2026). Regulatory Requirements For Approval of Vaccines In India In Comparison with The Philippines. European Journal of Pharmaceuticaland Medical Research, 13(11), 469–475.

This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 04/10/2026 **Article Revised on 25/10/2026** **Article Published on 01/11/2026**

ABSTRACT

This expanded review provides an in-depth comparative investigation into the regulatory frameworks governing vaccine evaluation, clinical trials, dossier evaluation, quality verification, and post-market oversight in India and the Philippines. Administered respectively by the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare (India) and the Food and Drug Administration (FDA Philippines) under the Department of Health, both systems strive to safeguard public safety while facilitating access to life-saving biological products. This work delineates the statutory legal foundations—specifically India's Drugs and Cosmetics Act (1940) and New Drugs and Clinical Trials Rules (NDCTR, 2019) versus the Philippines' Republic Act No. 3720 as amended by RA 9711 (FDA Act of 2009). Furthermore, the review contrasts national CTD structures against the ASEAN Common Technical Dossier (ACTD/eCTD), details multi-tiered biosafety and ethical committees (RCGM, GEAC, IRB/REC), compares lot-release mechanisms (CDL Kasauli vs. international lot release validation), evaluates emergency use authorization (EUA) pathways deployed during pandemic responses, and reviews ongoing pharmacovigilance and AEFI monitoring networks.

KEYWORDS: *Vaccines; Biologicals; CDSCO; FDA Philippines; NDCTR 2019; ACTD; Emergency Use Authorization; Pharmacovigilance; AEFI.*

1. INTRODUCTION

1.1 Background and Public Health Importance

Vaccination stands as one of the most transformative public health achievements in modern human history. By training the human immune system to recognize and neutralize specific pathogens, vaccines prevent millions of deaths annually from infectious diseases including measles, polio, diphtheria, pertussis, tetanus, hepatitis B, influenza, and more recently, SARS-CoV-2.[1,2] Unlike therapeutic pharmaceuticals administered to treat existing illnesses in symptomatic patients, vaccines are prophylactic biological preparations routinely administered to healthy individuals, including infants, pregnant women, and the elderly.[1,2] Consequently, the threshold for acceptable risk in vaccine safety is extraordinarily low, mandating rigorous regulatory oversight across every phase of discovery, preclinical testing, clinical development, commercial manufacturing, distribution, and post-market use.[1,2]

Developing a new vaccine is an intricate, capital-intensive process that historically spans 10 to 15 years. It demands seamless integration of molecular biology, immunology, bioprocess engineering, and clinical epidemiology.[2,9] Regulatory authorities act as essential gatekeepers/, evaluating complex multi-disciplinary data to ensure that every vaccine authorized for human use demonstrates consistent potency, uncompromised purity, robust safety, and reproducible clinical efficacy.[1,2,9]

1.2 Scope and Objectives of the Review

This review paper delivers a rigorous comparative analysis of the regulatory requirements and evaluation pathways for vaccine approval in two major Asian

nations: India and the Philippines.[1,4,19] While India represents a major global manufacturing powerhouse that supplies over 60% of the world's vaccines the Philippines represents a key dynamic market in the ASEAN region reliant on a combination of imported global biologicals, regional reliance mechanisms, and emerging domestic fill-finish infrastructure

The principal objectives of this review are as follows:

- To analyze the statutory legal foundations and administrative hierarchies governing vaccine registration in CDSCO (India) and FDA (Philippines).
- To delineate the classification, platforms, and manufacturing quality standards required for human biological vaccines To trace the lifecycle of clinical trial authorizations (INDs), phase I-IV protocols, ethics reviews, and local bridging data requirements.
- To examine dossier preparation formats, contrasting India's National CTD structure with the ASEAN Common Technical Dossier (ACTD/eCTD).
- To provide a side-by-side comparative table encompassing registration procedures, fees, review timelines, lot release mechanisms, and validity periods.[1,4,9,13,18,19]
- To evaluate emergency use authorization (EUA) frameworks, reliance mechanisms (WHO CRP), and pharmacovigilance networks (PvPI and AEFI systems).[5,8,9,12,15,17]

1.3 Regulatory Landscape Overview

In India, vaccine governance is anchored by the Central Drugs Standard Control Organization (CDSCO), operating under the Directorate General of Health Services, Ministry of Health and Family Welfare (MoHFW).[1,4] The Drugs Controller General of India (DCGI) serves as the central licensing authority.[1] Regulatory evaluation is supported by specialized Subject Expert Committees (SECs), the National Regulatory Authority (NRA) assessment panels, and biosafety committees including the Review Committee on Genetic Manipulation (RCGM) under the Department of Biotechnology (DBT) and the Genetic Engineering Appraisal Committee (GEAC) under MoEFCC.

In the Philippines, the Food and Drug Administration (FDA Philippines) functions under the Department of Health (DOH) as mandated by Republic Act No. 9711 (the FDA Act of 2009).[16,19] Vaccine evaluation falls under the specialized mandate of the Center for Drug Regulation and Research (CDRR). FDA Philippines closely aligns its biological evaluation standards with ASEAN harmonization guidelines and World Health Organization (WHO) prequalification standards.[5,8,10,11,13]

REGULATORY ARCHITECTURE COMPARISON: India operates under a central-state dual regulatory model where CDSCO handles new drug/vaccine approvals, clinical trial permits, and import licensing, while State Licensing Authorities (SLAs) oversee manufacturing facility inspections. In contrast, the Philippines FDA operates a centralized regulatory framework directly licensing both product registrations and manufacturing establishments nationwide.

2. Vaccine Classification, Platforms, and Mechanisms of Action

2.1 Traditional vs. Novel Vaccine Technologies

Vaccines are structurally and functionally diverse biological products classified according to their antigen design, delivery platform, and manufacturing process.[12,14] Regulatory requirements vary significantly depending on whether a vaccine utilizes established traditional modalities or novel gene-based platforms.[14,18]

- **Live Attenuated Vaccines (LAVs):** Formulated using weakened live pathogens capable of limited replication without causing disease in immunocompetent hosts. Examples include MMR, Oral Polio Vaccine (OPV), Yellow Fever, and BCG. LAVs elicit robust cell-mediated and humoral immunity but require rigorous biosafety testing and genetic stability monitoring to rule out reversion to virulence.
- **Inactivated (Killed) Vaccines:** Produced by inactivating whole viruses or bacteria using heat, radiation, or chemical agents such as beta-propiolactone or formaldehyde. Examples include Inactivated Polio Vaccine (IPV), Hepatitis A, and Whole Virion Rabies vaccines. Inactivated vaccines are non-replicating, exceptionally safe, but typically require adjuvants and multi-dose booster regimens.[14]
- **Toxoid Vaccines:** Formulated from purified bacterial exotoxins that have been chemically detoxified (toxoids) while preserving immunogenic epitopes. Key examples include Tetanus Toxoid and Diphtheria Toxoid. Regulatory evaluation focuses heavily on detoxification consistency and toxin neutralization assays.
- **Subunit & Conjugate Vaccines:** Utilize specific purified antigenic fragments (proteins or capsular polysaccharides). Conjugate vaccines chemically link weak capsular polysaccharide antigens to immunogenic carrier proteins (e.g., CRM197 or Tetanus Toxoid) to induce T-cell dependent memory in young children. Examples include Hib, Pneumococcal Conjugate (PCV13), and Meningococcal vaccines.
- **Recombinant Protein Vaccines:** Produced by insertion of antigen-encoding gene sequences into expression systems such as yeast (Saccharomyces cerevisiae), insect cells, or mammalian cell lines (CHO). Examples include Hepatitis B and Human Papillomavirus (HPV) vaccines. Detailed characterization of post-translational modifications and host cell protein impurities is mandatory.
- **Viral Vector Vaccines:** Employ non-replicating or replicating engineered carrier viruses (e.g.,

Recombinant Adenovirus ChAdOx1, Ad26, or Human Adenovirus Ad5) to deliver genetic instructions for the target antigen into host cells. Examples include Covishield and Sputnik V. Regulatory review encompasses vector backbones, viral clearance, and pre-existing anti-vector immunity

- **Nucleic Acid Vaccines (mRNA & DNA):** Represent cutting-edge platforms delivering synthetic mRNA encapsulated in Lipid Nanoparticles (LNPs) or plasmid DNA administered via needle-free injectors. Host cells translate the nucleic acid into target protein antigens, triggering strong humor and cellular immunity. Examples include Pfizer-BioNTech, Moderna, and ZyCoV-D

2.2 Immunological Mechanisms of Action

Following intramuscular, subcutaneous, or intradermal administration, vaccine antigens or nucleic acid sequences are taken up by local Antigen-Presenting Cells (APCs), predominantly dendritic cells and macrophages.[14] Dendritic cells process the antigens and migrate to draining lymph nodes, presenting antigenic peptides via Major Histocompatibility Complex Class I (MHC-I) and Class II (MHC-II) molecules to naive T-lymphocytes

Helper T-cells (CD4+) activate B-lymphocytes, stimulating their proliferation and differentiation into plasma cells capable of producing high-affinity antigen-specific immunoglobulins (IgG, IgA, IgM) that neutralize free pathogens and toxins. Concurrently, Cytotoxic T-cells (CD8+) are activated to eliminate infected host cells. The formation of long-lived memory B-cells and memory T-cells ensures rapid, robust secondary immune responses upon future natural exposure to the wild pathogen.

2.3 Quality by Design (QbD) in Vaccine Manufacturing

Modern vaccine manufacturing demands strict adherence to Quality by Design (QbD) principles. Critical Quality Attributes (CQAs)—such as antigen content, structural integrity, adjuvant adsorption efficacy, free toxin limits, sterility, endotoxin levels, and pH—must be defined during development and maintained within validated Critical Process Parameters (CPPs) during commercial batch processing.[14,18]

3. Preclinical Evaluation and Biosafety Standards

3.1 In Vitro and In Vivo Safety & Efficacy Testing

Before any candidate vaccine can be administered to human subjects in clinical trials, exhaustive preclinical testing must be executed under Good Laboratory Practice (GLP) compliant environments. Preclinical studies assess candidate immunogenicity, dose-response relationships, pharmacokinetics/biodistribution (for novel platforms like LNPs and viral vectors), and safety profiles.[14]

Essential preclinical safety evaluations include

- Single-Dose and Repeated-Dose Toxicity Studies: Conducted in relevant animal species (rodents and non-rodents) to detect system organ toxicity, local tolerance, and inflammatory changes.[14]
- Safety Pharmacology: Assessing potential acute neurological, cardiovascular, and respiratory effects.[14]
- Reproductive and Developmental Toxicity (DART): Mandatory for vaccines intended for administration to pregnant women or women of childbearing potential, evaluating embryo-fetal development and teratogenicity.
- Genotoxicity and Carcinogenicity: Required primarily for novel adjuvants, platform carriers, or integration-competent nucleic acid vectors.
- Challenge Studies in Animal Models: Demonstrating protective efficacy and neutralizing capacity following deliberate exposure to live virulent pathogens.

3.2 Biosafety Regulations: RCGM and GEAC in India

In India, vaccines involving genetically modified organisms (GMOs), recombinant DNA technology, or live viral vectors are subject to stringent multi-tiered biosafety oversight established under the Environmental Protection Act, 1986 and the 1989 Rules for Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells.

Applicants must obtain prior clearance from the Review Committee on Genetic Manipulation (RCGM), operating under the Department of Biotechnology (DBT), to conduct preclinical animal studies and containment protocols. For recombinant or genetically engineered vaccines, environmental risk assessments and containment clearance must also involve the Genetic Engineering Appraisal Committee (GEAC) under the Ministry of Environment, Forest and Climate Change (MoEFCC) prior to commercial manufacture.[4,18]

3.3 Institutional Oversight in the Philippines

In the Philippines, preclinical evaluation data and biosafety compliance are reviewed by the CDRR in close coordination with Institutional Biosafety Committees (IBCs) and the National Biosafety Committee of the Philippines (NCBP) under the Department of Science and Technology (DOST).[19] Sponsors submitting Investigational New Drug (IND) applications must furnish comprehensive animal safety data, GLP compliance certificates, and environmental biosafety risk mitigation plans.[19]

4. Clinical Trial Phases and Regulatory Governance

4.1 Multi-Phase Clinical Trial Requirements (Phase I to IV)

Clinical evaluation of vaccines progresses through four distinct sequential phases governed by Good Clinical

Practice (GCP) guidelines.[14] Each phase must satisfy pre-defined primary safety and immunogenicity endpoints before progressing to subsequent stages.

- **Phase I (First-in-Human / Safety Screening):** Small-scale open-label trials involving 20 to 100 healthy adult volunteers. Primary objectives are evaluating safety, tolerability, characterization of adverse events, and identification of preliminary dose levels and formulation regimens.
- **Phase II (Dose Ranging & Immunogenicity):** Randomized, controlled trials involving several hundred participants (200-500). Focuses on optimizing dose schedules, adjuvant ratios, evaluating immunogenicity (antibody titers, seroconversion rates, cell-mediated response), and assessing short-term safety profiles across targeted age demographics.[14]
- **Phase III (Confirmatory Efficacy & Safety):** Large-scale, multi-center, randomized, double-blind, placebo/comparator-controlled trials involving thousands to tens of thousands of participants (typically 3,000 to 30,000+). Phase III trials establish true efficacy against laboratory-confirmed disease, detect rare adverse events, and verify batch-to-batch manufacturing consistency.[14]
- **Phase IV (Post-Marketing Clinical Studies):** Conducted post-approval to evaluate real-world vaccine effectiveness in special populations (e.g., immunocompromised patients, pregnant women), monitor long-term immunity duration, and fulfill post-licensure commitments.[9,14]

4.2 Clinical Trial Authorization: India (Form CT-06 / NDCTR 2019)

In India, clinical trials for vaccines are regulated under Chapter III of the New Drugs and Clinical Trials Rules (NDCTR), 2019.[4] Sponsors must submit an application in Form CT-04 to CDSCO via the SUGAM digital portal.[1,4] The application is evaluated by specialized Subject Expert Committees (SECs) comprising clinical, biological, and pharmacological experts.

Upon SEC recommendation and verification of Ethics Committee (EC) registrations, CDSCO issues Clinical Trial Permission in Form CT-06. Clinical trial protocols must be registered on the Clinical Trials Registry - India (CTRI) prior to enrolling the first subject. Compensation mechanisms for trial-related injury or death are strictly enforced under NDCTR 2019 rules.

4.3 Clinical Trial Approval: Philippines (CDRR / REC Clearance)

In the Philippines, clinical trials involving investigational biologicals require prior authorization from the FDA CDRR. The sponsor must submit an Investigational New Drug (IND) application accompanied by technical dossiers, Investigator's Brochure (IB), protocol, and GCP documentation.

Simultaneously, trial protocols must undergo rigorous review by a accredited Institutional Review Board / Research Ethics Committee (REC) cleared by the Philippine Health Research Ethics Board (PHREB). Clinical trials must be registered in the Philippine Health Research Registry (PHRR).

4.4 Local Clinical Data & Bridging Study Requirements

A vital area of comparison between CDSCO and FDA Philippines lies in local clinical data mandates. CDSCO generally mandates local bridging clinical trials (Phase II/III) for foreign-developed vaccines to demonstrate safety and immunogenicity within the Indian ethnic population prior to full marketing authorization, unless explicitly waived during emergency public health crises.

FDA Philippines allows reliance on global Phase III clinical trial data generated in reputable international jurisdictions, provided the study population includes adequate Asian representation. However, local post-approval observational studies or phase IV commitments may be imposed.

5. Marketing Authorization Dossiers: CTD vs. ACTD

5.1 Structure of Indian National CTD

For marketing authorization in India, vaccine sponsors submit dossiers formatted according to CDSCO's National CTD guidelines, closely modeled after the International Council for Harmonisation (ICH) M4 format.

The dossier consists of five primary modules

- **Module 1 (Administrative & Regional):** Contains administrative forms (Form 44), labeling, prescribing information, package inserts, manufacturing licenses, state SLA approvals, and regulatory status in other countries.
- **Module 2 (CTD Summaries):** Provides high-level scientific overviews, including Quality Overall Summary (QOS), Preclinical Overview/Summary, and Clinical Overview/Summary.
- **Module 3 (Quality / CMC):** Comprehensive Chemical, Manufacturing, and Controls (CMC) documentation detailing seed lot characteristics, cell bank authentication, fermentation/harvesting processes, purification validation, adjuvant manufacturing, batch release specifications, and stability data.
- **Module 4 (Non-Clinical Study Reports):** Detailed GLP study reports covering toxicology, pharmacodynamics, safety pharmacology, and immunogenicity.
- **Module 5 (Clinical Study Reports):** Full GCP clinical study reports for Phase I-III trials, investigator signatures, protocol amendments, and statistical analysis plans (SAPs).

5.2 Structure of ASEAN Common Technical Dossier (ACTD)

FDA Philippines mandates submission of marketing applications formatted in accordance with the ASEAN Common Technical Dossier (ACTD) guidelines.

The ACTD framework is structured into four distinct Parts

- **Part I (Administrative Data and Product Information):** Includes FDA application forms, Certificate of Free Sale (CFS), Certificate of Pharmaceutical Product (CPP), GMP certificates, product labeling, and prescribing details.[13,19]
- **Part II (Quality Document):** Covers CMC requirements, master seed history, viral safety evaluations, batch analysis, specification limits, and stability testing under Zone IVb conditions (30°C / 75% RH).[13]
- **Part III (Non-Clinical Document):** Contains non-clinical overviews and study reports detailing preclinical safety and efficacy.[13]
- **Part IV (Clinical Document):** Encompasses clinical overviews, clinical summaries, Phase I-III study reports, safety databases, and pharmacovigilance plans.[13,19]

5.3 Module Comparison & Technical Requirements

While both CTD and ACTD cover identical core scientific domains, ACTD consolidates Module 2 summaries directly into Parts II, III, and IV. Additionally, stability testing parameters under ACTD specifically require real-time testing under Zone IVb climatic conditions (hot and humid) to account for Southeast Asian environmental profiles.[13,19]

6. Comprehensive Side-by-Side Comparative Analysis

To provide regulatory affairs professionals with a clear operational tool, Table 1 compares the legal, administrative, technical, and post-market parameters governing vaccine approval in India and the Philippines.[1,2,4,8,9,13,18,19]

Table no 1.

Parameter / Criteria	India (CDSCO)	Philippines (FDA Philippines)
Regulatory Authority	Central Drugs Standard Control Organization (CDSCO), headed by DCGI	Food and Drug Administration (FDA Philippines) / Center for Drug Regulation and Research (CDRR)
Parent Ministry	Ministry of Health and Family Welfare (MoHFW), Government of India	Department of Health (DOH), Republic of the Philippines
Primary Legislation	Drugs and Cosmetics Act, 1940; Drugs & Cosmetics Rules, 1945; NDCTR 2019	Republic Act No. 3720 amended by Republic Act No. 9711 (FDA Act of 2009)
Dossier Format	National CTD format (5 Modules, ICH aligned) submitted via SUGAM portal	ASEAN Common Technical Dossier (ACTD - 4 Parts) / eCTD format
Biosafety Oversight	Review Committee on Genetic Manipulation (RCGM/DBT) & GEAC (MoEFCC)	Institutional Biosafety Committees (IBC) & National Biosafety Committee (NCBP/DOST)
Clinical Trial Permit	Form CT-06 issued by CDSCO following SEC evaluation	Clinical Trial Approval (CTA) issued by CDRR following REC ethics clearance
Local Data Requirement	Local bridging clinical study (Phase II/III) mandatory, unless explicitly waived	Global Phase III data accepted if Asian subgroup data is represented; local IV optional
Application Forms	Form 44 (New Drug/Vaccine), Form 46 (Marketing), Form 28/29 (Mfg)	IND Application, Biological License Application (BLA) / Integrated Application Form
Official Review Timeline	Standard: 180 to 270 days; Accelerated/EUA: 30 to 90 days	Standard: 180 to 254 working days; Expedited/EUA: 30 to 60 days
Lot Release Mechanism	Mandatory official lot release and testing by Central Drugs Laboratory (CDL), Kasauli	Documentary verification of Summary Protocol and NRA Lot Release Certificate from origin
Marketing Authorization	Market Authorization / Manufacturing License issued under NDCTR 2019	Certificate of Product Registration (CPR) issued by CDRR
License Validity	Valid for 5 years; subject to renewal under Form 46 / NDCTR	Initial CPR valid for 2 years; Renewal CPR valid for 5 years
Pharmacovigilance	Pharmacovigilance Programme of India (PvPI) & National AEFI Committee	FDA Task Force Adverse Event Following Immunization (AEFI) & ADR Reporting System

7. Emergency Use Authorization (EUA) & Reliance Pathways

7.1 Special Legal Provisions for Public Health Crises

During public health emergencies, standard 12 to 18-month regulatory review timelines are incompatible with urgent population needs. Both India and the Philippines established formal legal mechanisms to grant Emergency Use Authorizations (EUAs) or expedited approvals for pandemic vaccines without compromising fundamental standards of safety, quality, and interim efficacy.[12,15,17]

7.2 Case Study: India's COVID-19 Vaccine Approvals

In India, CDSCO exercised powers under the Second Schedule of NDCTR 2019 (Accelerated Approval Process) to grant conditional approval / Restricted Use in Emergency Situation.[4,17] Key milestones include:

- **Covishield (ChAdOx1-S, Serum Institute of India):** Granted EUA in January 2021 based on UK/Brazil Phase III data and local Phase II/III bridging study safety and immunogenicity data.[2,17]
- **Covaxin (Whole Virion Inactivated, Bharat Biotech):** Granted conditional approval in January 2021 in 'clinical trial mode' based on robust Phase I/II immunogenicity and safety, followed by full EUA upon interim Phase III efficacy reporting.[2]
- **ZyCoV-D (DNA Vaccine, Zydus Cadila):** World's first human DNA vaccine granted EUA in August 2021, administered via a needle-free applicator.[2,17]
- **Corbevax & Covovax:** Granted EUA in late 2021, expanding protein subunit platform availability.[2]

7.3 Case Study: Philippines' Emergency Evaluation & WHO EUL Reliance

In the Philippines, Executive Order No. 121 issued in December 2020 granted the FDA Director General authority to issue EUAs for COVID-19 vaccines and treatments.[19] Under EO 121, FDA Philippines established an expedited review pathway leveraging WHO Emergency Use Listing (EUL) and Stringent Regulatory Authority (SRA) approvals.[5,6,8]

EUAs were granted to Pfizer-BioNTech, AstraZeneca, Sinovac, Sputnik V, Janssen, Covaxin, and Moderna following rigorous 21-day expedited expert panel evaluations. FDA Philippines further enforced Administrative Order No. 2020-0044 and 2020-0045, formalizing Abridged and Verification Review Pathways based on reliance principles.[5 6,8,19]

8. Lot Release, Quality Control, and Supply Chain Infrastructure

8.1 Batch Release Mechanisms: CDL Kasauli vs. FDA CDRR

A crucial regulatory step prior to commercial distribution is independent National Control Laboratory (NCL) batch release.

In India, statutory lot release is governed by the Central Drugs Laboratory (CDL), Kasauli. Every single commercial batch of vaccine manufactured domestically or imported must undergo rigorous physical, chemical, biological, and potency testing at CDL Kasauli before a Certificate of Analysis (CoA) and official release clearance are issued.

In the Philippines, FDA CDRR relies primarily on documentary lot release verification.[13,19] Importers must submit the Summary Protocol of Production and Control alongside official Lot Release Certificates issued by the NRA or NCL of the country of origin. FDA CDRR conducts random confirmatory quality testing at the National Reference Laboratory as warranted.

8.2 Manufacturing Infrastructure & Cold Chain Logistics

India is home to world-leading vaccine producers including Serum Institute of India, Bharat Biotech, Biological E, Zydus Lifesciences, and Indian Immunologicals, boasting massive end-to-end bulk synthesis and fill-finish capacities. Supply chains are supported by CDSCO's strict Good Distribution Practices (GDP) and the eVIN (Electronic Vaccine Intelligence Network) digital tracking system.

The Philippines historically relied on importing finished vaccine products. However, under recent DOH initiatives and public-private partnerships (e.g., Glovax-EuBiologics), the country is building domestic fill-finish facilities in Batangas to bolster national vaccine security. Archipelagic logistics present unique cold-chain challenges, managed via FDA's strict temperature-monitoring cold-chain rules.

9. Post-Marketing Surveillance, Pharmacovigilance & AEFI

9.1 PvPI and AEFI Reporting Systems in India

Post-approval safety monitoring in India is managed through the Pharmacovigilance Programme of India (PvPI), coordinated by the Indian Pharmacopoeia Commission (IPC) in collaboration with CDSCO. Adverse Events Following Immunization (AEFI) are investigated through a structured three-tier system comprising District, State, and National AEFI Committees.

Marketing Authorization Holders (MAHs) are required to submit Periodic Safety Update Reports (PSURs) every 6 months for the first 2 years post-licensure, and annually for the subsequent 2 years. Serious Adverse Events (SAEs) must be reported within 15 days.

9.2 Pharmacovigilance Framework in the Philippines

FDA Philippines operates a specialized Pharmacovigilance Section within the CDRR. MAHs must implement a Risk Management Plan (RMP) and appoint a qualified pharmacovigilance officer. AEFIs are reported through the VigiFlow platform and evaluated by the National AEFI Committee under DOH.[9,19]

10. Future Directions, Policy Harmonization, and Conclusion

10.1 Strategic Outlook for Regional Vaccine Security

The future of vaccine regulation in both nations is defined by digital transformation, adoption of Good Reliance Practices (GRelP), and technical harmonization.[11,13,19] Key emerging trends include:

- Digitalization of Dossier Reviews: Fully transition to eCTD formats and AI-assisted dossier evaluation platforms.[1,13]
- Adoption of WHO Reliance Principles: Greater utilization of WHO Collaborative Registration Procedures (CRP) to eliminate duplicate evaluations.
- Regulatory Preparedness for mRNA & Next-Gen Platforms: Developing clear guidance for gene therapy biologicals, mRNA LNPs, and pan-coronavirus vaccines.[14,18]
- Strengthening Regional Networks: Expanding ASEAN Sectoral Working Group cooperation and BIMSTEC regulatory partnerships.[13]

10.2 CONCLUSION

This comparative review highlights the robust scientific standards enforced by both India (CDSCO) and the Philippines (FDA CDRR) in authorizing vaccines.[1,19] While India's framework is built around domestic bridging trials, statutory central lot testing at CDL Kasauli, and National CTD submissions[1,2,4], the Philippines leverages ASEAN Common Technical Dossier (ACTD) formats, international reliance pathways, and imported NRA batch validations.[13,19] Both systems successfully balance rigorous safety and efficacy requirements with flexible emergency pathways, ensuring public health protection and vaccine confidence.

11. Compliance with Ethical Standards & References

ACKNOWLEDGMENTS

The authors express their sincere gratitude to the management of Sree Siddaganga College of Pharmacy, Tumkur, and Rajiv Gandhi University of Health Sciences, Karnataka, for providing academic support and research facilities. Special thanks are extended to our guide, Dr. P. Ashok Kumar, Professor, Department of Regulatory Affairs, for his guidance throughout this study

REFERENCES

1. CDSCO. Guidance document: Vaccine policy and market authorization procedures. New Delhi: Ministry of Health and Family Welfare, 2021. Available from:URL: https://cdsco.mohfw.gov.in
2. CDSCO. Annexure-I(b): Manufacturing permissions and statutory CDL lot release of human vaccines. New Delhi: CDSCO, 2026. Available from:URL: https://cdsco.gov.in
3. Press Information Bureau. CDSCO approves India's first dengue vaccine and novel biologicals. New Delhi: Government of India, 2026. Available from:URL: https://pib.gov.in
4. Ministry of Health and Family Welfare. Drugs and Cosmetics Act, 1940, Rules 1945, and New Drugs and Clinical Trials Rules (NDCTR), 2019. New Delhi: MoHFW; 2020.
5. FDA Philippines. Circular No. 2022-009: Implementing guidelines of AO No. 2020-0044 (WHO collaborative registration procedure). Manila: FDA, 2022. Available from:URL: https://www.fda.gov.ph
6. FDA Philippines. Circular No. 2022-004: Abridged and verification review pathways for biologicals (AO No. 2020-0045). Manila: FDA; 2022. Available from:URL: https://www.fda.gov.ph
7. FDA Philippines. Circular: Collaborative procedure for accelerated registration of WHO-prequalified vaccines. Manila: FDA, 2020.
8. Department of Health Philippines. Administrative Order No. 2020-0044: Adoption of WHO collaborative procedure. Manila: DOH, 2020.
9. FDA Philippines. Pharmacovigilance guidelines and AEFI monitoring for biologicals. Manila: FDA, 2021.
10. WHO. Collaborative registration procedure for WHO-prequalified vaccines. Geneva: World Health Organization, 2016. (Technical Report Series No. 996).
11. WHO. Good reliance practices in regulation of medical products: high-level principles. Geneva: World Health Organization, 2021. (TRS No. 1033, Annex 10).
12. WHO. Emergency use listing (EUL) procedure for vaccines against epidemic pathogens. Geneva: World Health Organization, 2020.
13. ASEAN Secretariat. ACTD/ACTR technical guidelines for biological and vaccine dossiers. Jakarta: ASEAN, 2018.
14. EMA. Guideline on clinical evaluation of vaccines for human use. Amsterdam: European Medicines Agency, 2018.
15. USFDA. Emergency use authorization for vaccines to prevent infectious disease threats. Silver Spring: Food and Drug Administration, 2020.
16. ANVISA. Brazilian regulatory framework and international reliance pathways for vaccines. Brasília: Agência Nacional de Vigilância Sanitária, 2021.
17. CDSCO. Guidance for accelerated approval and restricted emergency use of COVID-19 vaccines. New Delhi: CDSCO, 2021.
18. Department of Biotechnology. Biosafety guidelines for vaccine research and rDNA technology in India. New Delhi: DBT, 2020.
19. FDA Philippines. Administrative Order No. 2020-0045: Abridged and verification review pathways for drug registration. Manila: FDA., 2020.